Polo-Like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3516
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Polo-Like Kinase 1 Is a Therapeutic Target in High-Risk Neuroblastoma

Clinical Cancer Research
Cancer ResearchOncology
2010English

Modulating Polo-Like Kinase 1 as a Means for Cancer Chemoprevention

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2010English

Synthetic Lethality as a Targeted Approach to Advanced Prostate Cancer

2012English

Polo-Like Kinase 4 Inhibition: A Strategy for Cancer Therapy?

Cancer Cell
Cancer ResearchOncologyCell Biology
2014English

Genetic Depletion of Polo-Like Kinase 1 Leads to Embryonic Lethality Due to Mitotic Aberrancies

BioEssays
BiochemistryGeneticsMolecular Biology
2016English

Polo-Like Kinase-1 as a Novel Target in Neoplastic Mast Cells: Demonstration of Growth-Inhibitory Effects of Small Interfering RNA and the Polo-Like Kinase-1 Targeting Drug BI 2536

Haematologica
Hematology
2011English

Downregulation of Human Polo-Like Kinase Activity by Antisense Oligonucleotides Induces Growth Inhibition in Cancer Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

Polo-Like-Kinase 1: A Key Cellular Target for Anti-HBV Therapy?

Hepatology
MedicineHepatology
2017English

Enabling and Disabling Polo-Like Kinase 1 Inhibition Through Chemical Genetics

ACS Chemical Biology
BiochemistryMedicineMolecular Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy